Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA vaccine: A case report and brief literature review.


Journal

British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323

Informations de publication

Date de publication:
02 2023
Historique:
revised: 28 03 2022
received: 23 12 2021
accepted: 31 03 2022
pubmed: 19 4 2022
medline: 18 1 2023
entrez: 18 4 2022
Statut: ppublish

Résumé

Erythema nodosum (EN), the most common form of panniculitis, is a reactive inflammation of the subcutaneous fat clinically presented with a sudden onset of painful, erythematous, nodular, subcutaneous lesions, typically localized to the pretibial area. EN is commonly caused by numerous infections (especially beta-haemolytic streptococcal infections), autoimmune diseases (sarcoidosis), inflammatory bowel conditions and drugs. EN induced by Covid-19 vaccines is rarely reported. We describe an original clinical observation of a 75-year-old woman who presented with EN after receiving the second dose of BNT162b2, an mRNA vaccine.

Identifiants

pubmed: 35434826
doi: 10.1111/bcp.15351
pmc: PMC9111509
doi:

Substances chimiques

BNT162 Vaccine 0
COVID-19 Vaccines 0

Types de publication

Case Reports Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

536-540

Informations de copyright

© 2022 British Pharmacological Society.

Références

Requena L, Yus ES. Erythema nodosum. Dermatol Clin. 2008;26(4):425-438. doi:10.1016/j.det.2008.05.014
Schwartz RA, Nervi SJ. Erythema nodosum: A sign of systemic disease. Am Fam Physician. 2007;75(5):695-700.
Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R. Erythema nodosum: an experience of 10 years. Scand J Infect Dis. 2004;36(6-7):424-427. doi:10.1080/00365540410027184
Leung AKC, Leong KF, Lam JM. Erythema nodosum. World J Pediatr. 2018;14(6):548-554. doi:10.1007/s12519-018-0191-1
Cohen PR. Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum. Dermatol Ther. 2013;3(2):191-197. doi:10.1007/s13555-013-0035-9
Iannone P, Castellini G, Coclite D, et al. The need of health policy perspective to protect healthcare workers during COVID-19 pandemic. A GRADE rapid review on the N95 respirators effectiveness. PLoS ONE. 2020;15(6):e0234025. doi:10.1371/journal.pone.0234025
Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423-1437. doi:10.1016/j.jaip.2020.12.047
Mehta H, Handa S, Malhotra P, et al. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India. J Eur Acad Dermatol Venereol. 2022;36(1):e16-e18.
Aly MH, Alshehri AA, Mohammed A, et al. First case of erythema nodosum associated with Pfizer vaccine. Cureus. 2021;13(11):e19529. doi:10.7759/cureus.19529
Wu X, Lim JHL, Lee JSS, Chio MT-W. Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Int. 2022;6:107-108. doi:10.1016/j.jdin.2021.12.009
Cameli N, Silvestri M, Mariano M, Bennardo L, Nisticò SP, Cristaudo A. Erythema nodosum following the first dose of ChAdOx1-S nCoV-19 vaccine. J Eur Acad Dermatol Venereol. 2022;36(3):e161-e162. doi:10.1111/jdv.17762
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154
Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther. 2010;23(4):320-327. doi:10.1111/j.1529-8019.2010.01332.x
Polycarpou A, Walker SL, Lockwood DN. A systematic review of immunological studies of erythema nodosum leprosum. Front Immunol. 2017;8:233. doi:10.3389/fimmu.2017.00233
Kaliyadan F, Dharmaratnam AM. Erythema nodosum - an association with rabies vaccination. Dermatol Online J. 2008;14(6):22. doi:10.5070/D34vw9v3cs
Wu Y-L, Tsai M-H, Liu L-L. Erythema nodosum and hepatitis B: a case report and literature review. J Microbiol Immunol Infect. 2008;41(5):437-439.
Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous adverse reactions associated with SARS-CoV-2 vaccines. J Clin Med. 2021;10(22):5344.
McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55. doi:10.1016/j.jaad.2021.03.092
Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2021;186(1):142-152. doi:10.1111/bjd.20639
Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2022;49(1):34-41. doi:10.1111/cup.14104
Holmes GA, Desai M, Limone B, et al. A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology. JAAD Case Rep. 2021;16:53-57. doi:10.1016/j.jdcr.2021.07.038
Corbeddu M, Diociaiuti A, Vinci MR, et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 vaccine: an Italian single-centre case series. J Eur Acad Dermatol Venereol. 2021;35(8):e483-e485. doi:10.1111/jdv.17268
Tomayko MM, Damsky W, Fathy R, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021;148(3):750-751. doi:10.1016/j.jaci.2021.06.026
Annabi E, Dupin N, Sohier P, et al. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature. J Eur Acad Dermatol Venereol. 2021;35(12):e847-e850. doi:10.1111/jdv.17578
Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D, Vakirlis E. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021;35(12):e857-e859. doi:10.1111/jdv.17582
Vastarella M, Picone V, Martora F, Fabbrocini G. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series. J Eur Acad Dermatol Venereol. 2021;35(12):e845-e846. doi:10.1111/jdv.17576
Rademacher J-G, Tampe B, Korsten P. First report of two cases of Löfgren's syndrome after SARS-CoV-2 vaccination: Coincidence or causality? Vaccine. 2021;9(11):1313.
Salvatore MA, Lynch PJ. Erythema nodosum, estrogens, and pregnancy. Arch Dermatol. 1980;116(5):557-558. doi:10.1001/archderm.1980.01640290067014
Suter P, Mooser B, Thien HPPH. Erythema nodosum as a cutaneous manifestation of COVID-19 infection. BMJ Case Rep. 2020;13(7):e236613.
Watad A, De Marco G, Mahajna H, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccine. 2021;9(5):435.
Polat A, Dinulescu M, Fraitag S, et al. Skin manifestations among GATA2-deficient patients. Br J Dermatol. 2018;178(3):781-785. doi:10.1111/bjd.15548

Auteurs

Ferdaous Chahed (F)

Department of Clinical Pharmacology, University Hospital of Monastir. University of Monastir, Tunisia.

Najah Ben Fadhel (N)

Department of Clinical Pharmacology, University Hospital of Monastir. University of Monastir, Tunisia.

Haifa Ben Romdhane (H)

Department of Clinical Pharmacology, University Hospital of Monastir. University of Monastir, Tunisia.

Monia Youssef (M)

Department of Dermatology, University Hospital of Monastir. University of Monastir, Tunisia.

Seifeddine Ben Hammouda (S)

Department of Pathology, University Hospital of Monastir. University of Monastir, Tunisia.

Amel Chaabane (A)

Department of Clinical Pharmacology, University Hospital of Monastir. University of Monastir, Tunisia.

Karim Aouam (K)

Department of Clinical Pharmacology, University Hospital of Monastir. University of Monastir, Tunisia.

Nadia Ben Fredj (N)

Department of Clinical Pharmacology, University Hospital of Monastir. University of Monastir, Tunisia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH